Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seiden

Showing results (481-490 of 978) with videos related to

Pageof 98
Sort By:
Vaccine|December 6, 2016
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 studyRobert W Frenck, C Buddy Creech, Eric A Sheldon, et al.
Cancer Biology & Therapy|December 7, 2007
Mechanisms of Cables 1 gene inactivation in human ovarian cancer developmentHideo Sakamoto, Anne M Friel, Antony W Wood, et al.
Cancer Research|May 31, 2002
Molecular profiling of non-small cell lung cancer and correlation with disease-free survivalDennis A Wigle, Igor Jurisica, Niki Radulovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic studyR Garcia-Carbonero, J G Supko, R G Maki, et al.
Vaccine|November 22, 2016
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trialC Buddy Creech, Robert W Frenck, Eric A Sheldon, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.
Circulation Research|February 16, 2013
The Congenital Heart Disease Genetic Network Study: rationale, design, and early results, Bruce Gelb, Martina Brueckner, et al.
Lancet (London, England)|November 21, 2024
The next 1000 days: building on early investments for the health and development of young childrenCatherine E Draper, Aisha K Yousafzai, Dana C McCoy, et al.
The Journal of Pediatrics|June 20, 2020
Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York CityShubhi Kaushik, Scott I Aydin, Kim R Derespina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyR Garcia-Carbonero, J G Supko, J Manola, et al.
Pageof 98

Showing results (481-490 of 978) with videos related to

Sort By:
Pageof 98
Vaccine|December 6, 2016
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 studyRobert W Frenck, C Buddy Creech, Eric A Sheldon, et al.
Cancer Biology & Therapy|December 7, 2007
Mechanisms of Cables 1 gene inactivation in human ovarian cancer developmentHideo Sakamoto, Anne M Friel, Antony W Wood, et al.
Cancer Research|May 31, 2002
Molecular profiling of non-small cell lung cancer and correlation with disease-free survivalDennis A Wigle, Igor Jurisica, Niki Radulovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic studyR Garcia-Carbonero, J G Supko, R G Maki, et al.
Vaccine|November 22, 2016
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trialC Buddy Creech, Robert W Frenck, Eric A Sheldon, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi, Martin C Mihm, Robert J Soiffer, et al.
Circulation Research|February 16, 2013
The Congenital Heart Disease Genetic Network Study: rationale, design, and early results, Bruce Gelb, Martina Brueckner, et al.
Lancet (London, England)|November 21, 2024
The next 1000 days: building on early investments for the health and development of young childrenCatherine E Draper, Aisha K Yousafzai, Dana C McCoy, et al.
The Journal of Pediatrics|June 20, 2020
Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York CityShubhi Kaushik, Scott I Aydin, Kim R Derespina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyR Garcia-Carbonero, J G Supko, J Manola, et al.
Pageof 98